Axogen Inc. (AXGN) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
Axogen Inc. (AXGN) advanced +0.77% to $49.63 as options desks priced 58% call premium vs. 42% put protection around the $49 max-pain magnet. Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.
AI giants are planning up to US$828b in data center and chip spending this year, and that level of capital tied up in one corner of the market has many investors rethinking concentration risk. Capital that chases one sto
Axogen (AXGN) is evolving from a growth story to the default procedural platform in peripheral nerve repair, protected by a regulatory moat for the next...
Canaccord Genuity analyst Caitlin Roberts maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $55 to $60.
Leerink Partners analyst Mike Kratky maintains Axogen (NASDAQ:AXGN) with a Outperform and raises the price target from $52 to $56.
Here is how AxoGen (AXGN) and BioCryst Pharmaceuticals (BCRX) have performed compared to their sector so far this year.
Barclays analyst Christopher Pasquale maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $50 to $60.
Truist Securities analyst Ravi Misra maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $53 to $60.
Wells Fargo analyst Larry Biegelsen maintains Axogen (NASDAQ:AXGN) with a Overweight and raises the price target from $48 to $56.
Analysts raised targets for Microsoft, VF, Glaukos, Hilton, AxoGen and Brinker; Renasant’s target was cut and its rating downgraded.
HC Wainwright & Co. analyst Yi Chen maintains Axogen (NASDAQ:AXGN) with a Buy and raises the price target from $53 to $56.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +20.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on AXGN today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for AXGN. Explore sector supply chains on /butterfly.
Why AXGN Stock advanced +0.77% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-3% return on capital) under elevated 10-year interest-rate pressure.